Investors Brace For Impact: ViewRay, Inc. (VRAY), Lipocine Inc. (LPCN)

ViewRay, Inc. (NASDAQ:VRAY) recently had a high trading volume day. The volume for the company on 11-Jan-18 was recorded to be 1.94 million contracts. Over the past three months, the average daily trading volume came in at about 0.86 million shares per day. The regular trading started at $9.75 but as the trading progresses, the stock escalated, ending the session with a gain of 5.2%. Its shares last exchanged hands at a price of $10.12 apiece.

VRAY Is 10.4% Away From SMA20

The shares of the company (VRAY) staged the smart recovery as has roared back some 236.21% after stumbling to its new 52-weeks low. The share price volatility of the stock remained at 9.57% for the month and by reducing the timeframe to just a week, the volatility stood at 5.89%. As for the shares, it has gone above the 20 days moving average and is now hovering within a distance of 10.4%. Currently the price is sitting at 14.33% higher than its 50 days moving average. Analyzing the last five market sessions, the stock was able to report 7.43% gains, thus going up by 46.57%, compared with its 200-day moving average of $6.93. Also, a 218.24% expansion in ViewRay, Inc. (VRAY) witnessed over the past one year opens up opportunity to go after even more gains

Lipocine Inc. (NASDAQ:LPCN) Has 2 Buy or Better Ratings

Lipocine Inc. (LPCN) was also brought into the spotlight with a -$1.59 drop. As the regular session came to an end, the price changed by -45.95% to $1.87. The trading of the day started with the price of the stock at $1.75. However, at one point, in the middle of the day, the price touched a high of $2.14 before it finally returned some of the gains. Analyzing LPCN this week, analysts seem to be content with keeping to their bright forecast call at 1.5. Lipocine Inc. analysts gave 2 buy-equivalent recommendations, 0 sells and 0 holds. This company shares tumbled -64.92% from their most recent record high of $5.33 and now hold $43.33 million in market value of equity.

Lipocine Inc. Underpriced by 702.14%

LPCN’s mean recommendation on Reuter’s scale has so far not been altered from 1.5 thirty days ago to 1.5 now. This is an indication of a buy consensus from the analysts’ society. They expect that Lipocine Inc. (LPCN) price will be reaching a mean target of $12 a share. This implies that they believe the stock has what it takes to lift the price another 541.71%. The recent close goes a long way in suggesting that the stock price is being underpriced by a 702.14% compared to the most bullish target.

Lipocine Inc. (LPCN) Returns -45.64% This Year

The company during the last trade was able to reach a volume of 5 million shares. That activity is comparable to their recent volume average trend of nearly 0.32 million shares which they recorded over a period of three months. The stock price volatility for last week at the close of regular trading was 7.1%, pushing the figure for the whole month to now reaching 16.99%. Lipocine Inc. price was kept to a minimum $1.67 in intra-day trade and has returned -45.64% this year alone. At a certain point in the past four quarters, the shares traded as low as $2.90 but made a -35.42% recovery since then.

Previous articleStocks Stepping Onto Center Stage: Synergy Pharmaceuticals Inc. (SGYP), SemiLEDs Corporation (LEDS)
Next articleWhich insiders are selling TRACON Pharmaceuticals, Inc. (TCON)?